Skip to content

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01622140
Enrollment
21334
Registered
2012-06-18
Start date
2012-10-31
Completion date
2020-12-31
Last updated
2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Tuberculosis Infection, Tuberculosis

Keywords

T-SPOT.TB, QuantiFERON-TB Gold In-Tube, Latent tuberculosis infection, Tuberculin skin test, Discordance, Predictive value, Tuberculosis disease development

Brief summary

This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease. The study will assess the relative performance and cost of three diagnostic tests for latent tuberculosis infection (tuberculin skin test, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB) and will examine the rates of positive results among the cohort. This study will also determine the risk and rate of progression to active TB disease, overall and by the results of the three tests.

Interventions

None listed

Sponsors

Centers for Disease Control and Prevention
Lead SponsorFED

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Study participants must be at high risk for latent tuberculosis infection or at high risk for progression to tuberculosis disease, including being a: • Close contact of a person with pulmonary tuberculosis who is part of a current contact investigation and the index/source case meets the following criteria: 1. Culture-positive, OR 2. Culture-negative and smear positive and nucleic acid amplification test-positive. Participants may be enrolled before the culture results for the index/source case are available. If the criteria described above are not met once results are available, the participant will be terminated from the study and any collected data will be immediately destroyed. A close contact is defined as spending 15 or more hours over a week's period in a shared airspace with a person with active pulmonary tuberculosis while that person was presumed to be infectious. * Foreign-born person from a high risk country. * Foreign-born person from a medium risk country who moved to the United States within the past 5 years. * Person who has spent at least 30 days in total in a high risk country within the last 5 years. * Person belonging to a population with a prevalence of latent tuberculosis infection ≥ 25% as demonstrated by local surveys. These populations will vary by site; examples include Mexican immigrants in San Diego, California or homeless drug users in Baltimore, Maryland. * HIV-positive person. 2. Study participants (or a parent/guardian, if applicable) must be willing and able to provide informed consent. 4.2 Subject

Exclusion criteria

Subjects meeting any of the

Design outcomes

Primary

MeasureTime frame
Latent tuberculosis infection3 days
Tuberculosis disease at 6 months6 months
Tuberculosis disease at 12 months12 months
Tuberculosis disease at 18 months18 months
Tuberculosis disease at 24 months24 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026